Olympus has successfully completed the transfer of its orthopedic business to entities established by Polaris Capital. The deal, which includes the sale of all shares of its subsidiaries Olympus Terumo Biomaterials Corporation and FH Ortho, is expected to have an immaterial impact on Olympus’s consolidated operating profit for the fiscal year ending March 31, 2025.
Olympus acquired FH ORTHO in 2020, at the time supporting Olympus’ focus on expanding in the field of orthopedic minimally invasive surgery (MIS) organically and through M&A. FH’s spine products, the LP-ESP lumbar disc replacement and the CP-ESP cervical disc replacement, were not included in the transaction; the line was spun out to Spine Innovations.
FH ORTHO was focused on MIS procedures in ligament repair, foot & ankle and trauma surgery. Olympus Terumo Biomaterials distributed bone substitutes and high tibial osteotomy plates and screws. Olympus had also developed the first ultrasound device indicated for arthroscopic surgery.
Polaris will support the planning and execution of growth strategies while leveraging existing strengths of the businesses by strengthening management functions, enhancing development and sales structure, improving operations, promoting ESG and digitalization, as well as accelerating overseas expansion through realizing synergies between Olympus Terumo Biomaterials and FH Ortho.
Olympus has successfully completed the transfer of its orthopedic business to entities established by Polaris Capital. The deal, which includes the sale of all shares of its subsidiaries Olympus Terumo Biomaterials Corporation and FH Ortho, is expected to have an immaterial impact on Olympus’s consolidated operating profit for the fiscal year...
Olympus has successfully completed the transfer of its orthopedic business to entities established by Polaris Capital. The deal, which includes the sale of all shares of its subsidiaries Olympus Terumo Biomaterials Corporation and FH Ortho, is expected to have an immaterial impact on Olympus’s consolidated operating profit for the fiscal year ending March 31, 2025.
Olympus acquired FH ORTHO in 2020, at the time supporting Olympus’ focus on expanding in the field of orthopedic minimally invasive surgery (MIS) organically and through M&A. FH’s spine products, the LP-ESP lumbar disc replacement and the CP-ESP cervical disc replacement, were not included in the transaction; the line was spun out to Spine Innovations.
FH ORTHO was focused on MIS procedures in ligament repair, foot & ankle and trauma surgery. Olympus Terumo Biomaterials distributed bone substitutes and high tibial osteotomy plates and screws. Olympus had also developed the first ultrasound device indicated for arthroscopic surgery.
Polaris will support the planning and execution of growth strategies while leveraging existing strengths of the businesses by strengthening management functions, enhancing development and sales structure, improving operations, promoting ESG and digitalization, as well as accelerating overseas expansion through realizing synergies between Olympus Terumo Biomaterials and FH Ortho.
Copy to clipboard 
